| Species |
Human |
| Protein Construction |
| hFc |
TAFA2/FAM19A2 (Ala31-His131)_x000D_
Accession # Q8N3H0-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
36.74 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tafa is a family of small secreted proteins with conserved cysteine residues and restricted expression in the brain. It is composed of five highly homologous genes referred to as Tafa-1 to -5. FAM19A2/TAFA-2 induces skeletal stem cell migration through the activation of Rac1-p38 signaling and is highly abundant in the central nervous system and MIP1α regulates energy balance. |
| Synonyms |
TAFA2; FAM19A2; TAFA-2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
